Chestnut Hill, MA, United States of America

William R Sellers

This inventor holds 13 USPTO granted patents, plus 1 CIPO patent and 5 EPO patents. Top assignees: Dana-Farber-Cancer Institute Inc., The General Hospital Corporation, Whitehead Institute for Biomedical Research. Active years: 1998-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: William R Sellers. Retrieved from https://idiyas.com/inventor/william-r-sellers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13

% Patents Active = 84.6

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 6.5

ph-index = 7

Forward Citations = 631(Granted Patents)

Location History:

Brookline, MA (US) (1998 - 2011)
Chestnut Hill, MA (US) (2005 - 2024)

Company Filing History:

13 out of 1,266

Dana-Farber-Cancer Institute Inc.

patents

8 out of 3,071

The General Hospital Corporation

patents

2 out of 317

Whitehead Institute for Biomedical Research

patents

4. 1 out of 1,425

The Brigham and Women's Hospital, Inc.

patents

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12006555 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2024-06-11),

2. 10669589 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2020-06-02),

3. 10000815 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2018-06-19),

4. 9035036 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2015-05-19),

5. 8465916 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2013-06-18),

6. 8105769 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2012-01-31),

7. 7981609 - Methods for identifying and using SNP panels (2011-07-19),

8. 7964349 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2011-06-21),

9. 7501248 - Prostate cancer diagnosis and outcome prediction by expression analysis (2009-03-10),

10. 7294468 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2007-11-13),

11. 6949342 - Prostate cancer diagnosis and outcome prediction by expression analysis (2005-09-27),

12. 5981723 - Retinoblastoma-associated protein 1 CDNA (1999-11-09),

13. 5759803 - Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and (1998-06-02),

Title: The Innovative Contributions of William R. Sellers

Introduction

William R. Sellers is a prominent inventor based in Chestnut Hill, MA (US). He has made significant contributions to the field of cancer research, holding a total of 13 patents. His work focuses on developing methods to improve cancer treatment outcomes through targeted therapies.

Latest Patents

Among his latest patents is a method to determine the responsiveness of cancer to epidermal growth factor receptor (EGFR) targeting treatments. This patent discloses methods and reagents for assessing how well cancer patients may respond to EGFR-targeting treatments. The detection of specific mutations allows for the administration of drugs like gefitinib and erlotinib to those patients most likely to benefit from these therapies.

Career Highlights

Throughout his career, William R. Sellers has worked with esteemed organizations such as the Dana-Farber Cancer Institute and The General Hospital Corporation. His research has been pivotal in advancing the understanding of cancer treatment and improving patient outcomes.

Collaborations

Some of his notable coworkers include Daphne Winifred Bell and Daniel Arie Haber. Their collaborative efforts have contributed to the success of various research projects and innovations in cancer treatment.

Conclusion

William R. Sellers continues to be a key figure in cancer research, with his innovative patents paving the way for more effective treatments. His dedication to improving patient care through scientific advancements is commendable.

Profile summary based on public USPTO records.